Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities

BMC Infectious Diseases

Volumn 14, Issue , 2014, Pages

  Heimer, Robert ^a   Eritsyan, Ksenia ^b   Barbour, Russell ^a   Levina, Olga S ^b  

^a YALE UNIVERSITY   (United States)

^b NGO Stellit   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE;

ADULT; ARTICLE; DRUG ABUSE; FEMALE; HARM REDUCTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION DRUG USE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEEDLE SHARING; RUSSIAN (PEOPLE); SEROPREVALENCE; SOCIAL NETWORK; CITY; COMPLICATION; PREVALENCE; RUSSIAN FEDERATION; SUBSTANCE ABUSE; TRANSMISSION; YOUNG ADULT;

ADULT; CITIES; FEMALE; HEPATITIS C; HUMANS; MALE; PREVALENCE; RUSSIA; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84964313240     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-S6-S12     Document Type: Article

References (63)

1. Aceijas C, Rhodes T: Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007, 18:352-358.
2. Human Rights Watch: Rehabilitation Required: Russia's Human Rights Obligation to Provide Evidence-based Drug Dependence Treatment. Human Rights Watch New York, USA; 2007 [http://www.hrw.org/en/node/10608/].
3. UN Office on Drugs and Crime: World Drug Report, 2009. UNODC Vienna, Austria; 2009 [http://www.unodc.org/documents/wdr/WDR_2009/WDR2009_eng_web.pdf].
4. Abdala N, Carney JM, J DA, Klimov N, Ostrovski D, Somlai AM, Kozlov AP, Heimer R: Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St. Petersburg, Russia. Internatl J STD & AIDS 2003, 14:697-703.
5. Rhodes T, Platt L, Judd A, Mikhailova LA, Sarang A, Wallis N, Alpatova T, Hickman M, Parry JV: Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. Internatl J STD & AIDS 2005, 16:749-754.
6. Ostrovski DV: WHO drug injecting study in St. Petersburg. Phase two. Presented at: XIV Internatl AIDS Conf: 2002; Barcelona, Spain; 2002, WePeC6081.
7. Rhodes T, Lowndes C, Judd A, Mikhailova LA, Sarang A, Rylkov A, Tichonov M, Lewis K, Ulyanova N, Alpatova T, et al: Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS 2002, 16:F25-F31.
8. Krupitsky EM, Zvartau EE, Lioznov DA, Tsoy MV, Egorova VY, Belyaeva TV, Antonova TV, Brazhenko NA, Zagdyn ZM, Verbitskaya EV, et al: Comorbidity of infectious and addictive diseases in St. Petersburg and the Leningrad Region, Russia. Eur Addiction Res 2006, 12:12-19.
9. Paintsil E, Verevochkin SV, Dukhovlinova E, Niccolai LM, Barbour R, White E, Toussova OV, Alexander L, Kozlov AP, Heimer R: Hepatitis C Virus Infection among drug injectors in St. Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction 2009, 104:1881-1890.
10. Rhodes T, Platt L, Maximova S, Koshkina E, Latishevskaya N, Hickman M, Renton A, Bobrova N, McDonald T, Parry JV: Prevalence of HIV, hepatitis Cand syphilis among injecting drug users in Russia: a multi-city study. Addiction 2006, 101:252-266.
11. Savilov ED, Maltsev MV: [Epidemiological characteristic of viral hepatitis C in large industrial city settings]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii 2007, 1: 70-72.
12. Reuters: Medivir AB announces Russian Ministry of Health has approved Sovriad (simeprevir). 2014 [http://in.reuters.com/finance/stocks/MVIRb.ST/key-developments/article/2949949].
13. Eritsyan K, Heimer R, Barbour R, Odinokova V, White E, Rusakova MM, Levina OS: Individual-, network-, and city-level factors associated with HIV prevalence among people who inject drugs in eight Russian cities. BMJ Open 2013, 3:6.
14. Niccolai LM, Shcherbakova IS, Toussova OV, Kozlov AP, Heimer R: The potential for bridging of HIV transmission in Russian Federation: Sex risk behaviors and HIV prevalence among drug users (DUs) and their non-DU sex partners. J Urban Health 2009, 86(Suppl 1):131-143.
15. Platt L, Rhodes T, Hickman M, Mikhailova L, Lisetsky K, Sarang A, Lewis K, Parry J: Changes in HIV prevalence and risk among new injecting drug users in a Russian city of high HIV prevalence. J Acquir Immune Defic Syndr 2008, 47:623-631.
16. Rhodes T, Sarang A, Bobrik A, Bobkov A, Platt L: HIV transmission and HIV prevention associated with injecting drug use in the Russian Federation. Internatl J Drug Policy 2004, 15:1-16.
17. Shaboltas AV, Toussova OV, Hoffman IF, Heimer R, Verevochkin SV, Ryder RW, Khoshnood K, Perdue T, Masse BR, Kozlov AP: HIV prevalence, socio-demographic and behavioral correlates and recruitment methods among injection drug users in St. Petersburg, Russia. J Acquir Immune Defic Syndr 2006, 41:657-663.
18. Heckathorn DD: Respondent-driven sampling; a new approach to the study of hidden populations. Soc Problems 1997, 44:174-199.
19. Heckathorn DD, Semaan S, Broadhead RS, Hughes JJ: Extensions of Respondent-Driven Sampling: A New Approach to the Study of Injection Drug Users Aged 18-25. AIDS & Behav 2002, 6:55-67.
20. Heckathorn D: Respondent driven sampling II: Deriving valid population estimates from chain-referral samples of hidden populations. Social Problems 2002, 49:11-34.
21. Salganik MJ, Heckathorn DD: Sampling and estimation in hidden populations using respondent-driven sampling. Sociolog Methodol 2004, 34:193-240.
22. Volz E, Heckathorn DD: Probability Based Estimation Theory for Respondent-Driven Sampling. J Official Stats 2008, 24:79-97.
23. Family Health International: Behavioral Surveillance Surveys: Guidelines for Repeated Behavioral Surveys in Populations at Risk of HIV. Arlington, VA: Family Health International; 2000 [http://www.fhi360.org/about-us/contact-us].
24. Abdala N, Grund J-PC, Tolstov Y, Kozlov AP, Heimer R: Can Homemade Injectable Opiates Contribute to the HIV Epidemic among Injection Drug Users in the Countries of the Former Soviet Union? Addiction 2006, 101:731-737.
25. Paoli L: The development of an illegal market. Drug consumption and Trade in Post-Soviet Russia. Br J Criminology 2002, 42(1):21-39.
26. Demirbüken H, Mili H, Spassova Y, Azizi H, Pashtoon SJ: Opiate flows through northern Afghanistan and Central Asia: a threat assessment. Vienna, Austria: UN Office on Drugs & Crime; 2012 [http://www.unodc.org/documents/data-and-analysis/Studies/Afghanistan_northern_route_2012_web.pdf].
27. Kozlov AP, Shaboltas AV, Toussova OV, Verevochkin SV, Masse BR, Beauchamp G, Sheldon W, Miller WC, Heimer R, Ryder RW, et al: HIV incidence and factors associated with HIV acquisition among injection drug users in St. Petersburg, Russia. AIDS 2006, 20:901-906.
28. Fox J: The R Commander: A basic statistics graphical user interface to R. J Stat Software 2005, 14(9):1-42.
29. R Core Team: R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013 [http://www.Rproject. org/].
30. Chongsuvivatwong V: Package 'epicalc', manual. Vienna, Austria: R Foundation for Statistical Computing; 2013 [http://cran.r-project.org/web/packages/epicalc/epicalc.pdf].
31. Chongsuvivatwong V: Analysis of epidemiological data using R and Epicalc,. Hat Yai, Thailand: The Epidemiology Unit, Prince of Songkla University; 2008 [http://www.who.int/tdr/publications/training-guidelinepublications/analysis-epidemiological-data/en/].
32. Akaike H: A new look at the statistical model identification. IEEE Transactions on Automatic Contr 1974, 19:716-723.
33. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE: Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Amer J Publ Health 1996, 85:655-661.
34. van Ameijden EJC, van den Hoek JAR, Mientjes GHC, Coutinho RA: A longitudinal study of the incidence and transmission patterns of HIV, HBV, and HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993, 9:255-262.
35. van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM: Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ 1998, 317:433-437.
36. Muga R, Sanvisens A, Bolao F, Tor J, Santesmases J, Pujol R, Tural C, Langohr K, Rey-Joly C, Munoz A: Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987-2001. Drug & Alc Dependence 2006, 82(Suppl 1):S29-S33.
37. Short LJ, Bell DM: Risk of occupational infection with blood-borne pathogens in operating and delivery room settings. Amer J Infect Contr 1993, 21:343-350.
38. Abdala N, Reyes R, Carney JM, Heimer R: Survival of HIV-1 in syringes: Effects of temperature during storage. Subst Use Misuse 2000, 35:1-19.
39. Abdala N, Stephens PC, Griffith BP, Heimer R: Survival of Human Immunodeficiency Virus type 1 in syringes. J Acquir Immune Defic Syndr Human Retrovir 1999, 20:73-80.
40. Heimer R: Syringe exchange programs: lowering the transmission of syringe-borne diseases and beyond. Publ Health Rpts 1998, 113(suppl 1):67-74.
41. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R: Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis 2010, 202:984-990.
42. Hagan H, Thiede H, Des Jarlais DC: Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 2004, 15:543-549.
43. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, Monterosso ER, Garfein RS: Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Amer J Epidemiol 2002, 155:645-653.
44. Spittal PM, Pearce ME, Chavosh iN, Christian WM, Moniruzzaman A, Teegee M, Schechter MT: The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities. BMC Public Health 2012, 12:632.
45. Heimer R, Kinzly ML, He H, Abdala N: The effect of acids on the survival of HIV during drug injection. J Acquir Immune Defic Syndr 2007, 144-150.
46. Goel S, Salganik MJ: Assessing respondent-driven sampling. Proc Natl Acad Sci U S A 2010, 107:6743-6747.
47. Guntuboyina A, Barbour R, Heimer R: On the impossibility of constructing good population mean estimators in a realistic Respondent Driven Sampling model. Cornell University Library 2012 [arXiv.org].
48. Heimer R: Critical issues and further questions about respondent-driven sampling: comment on Ramirez-Valles, et al. (2005). AIDS Behav 2005, 9:403-408.
49. European Monitoring Centre on Drugs and Drug Abuse: Data: statistical bulletin 2013. Lisbon, Portugal; 2013 [http://www.emcdda.europa.eu/stats13/inffig6a].
50. Castro-Sanchez A, Shkedy Z, Hens N, Aerts M, Geskus R, Prins M, Wiessing L, Kretzschmar M: Epidemiol & Infect 2012, 140:1064-1074.
51. Csete J: Lessons not learned: Human rights abuses and HIV/AIDS in the Russian Federation. Human Rights Watch 2004, 16(5):1-62.
52. Cohen J: Late for the Epidemic: HIV/AIDS in Eastern Europe. Science 2010, 329:160-164.
53. Badrieva L, Karchevsky E, Irwin K, Heimer R: Reduced Injection-Related HIV-1 Risk Associated with Participation in a Harm Reduction Project in Kazan, Russia. AIDS Educ Prevent 2007, 41:979-999.
54. Pape U: The Politics of HIV/AIDS in Russia. Abingdon, Oxon, UK: Taylor & Francis; 2013.
55. Paintsil E, Binka M, Patel A, Lindenbach BD, Heimer R: Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission. J Infect Dis 2014, 209:1205-1211.
56. Grau LE, Green TC, Singer M, Bluthenthal RN, Marshall PA, Heimer R: Getting the message straight: effects of a brief hepatitis prevention intervention among injection drug users. Harm Reduction J 2009, 2009: e36.
57. Grund J-PC, Kaplan CD, Adriaans NFP, Blanken P, Huisman J: The limitations of the concept of needle sharing: the practice of frontloading. AIDS 1990, 4:819-821.
58. Koester SK, Glanz J, Baron A: Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS & Behav 2005, 9:27-39.
59. Butler WE: HIV/AIDS and drug misuse in Russia: Harm reduction programmes and the Russian legal system. London, UK: International Family Health; 2003.
60. Fedorova EV, Skochilov RV, Heimer R, Case P, Beletsky L, Grau LE, Kozlov AP, Shaboltas AV: Access to syringes for HIV prevention for injection drug user in St. Petersburg, Russia: syringe purchase test study. BMC Public Health 2013, 13:183.
61. Sarang A, R T, Platt L: Access to syringes in three Russian cities: Implications for syringe distribution and coverage. Internatl J Drug Policy 2008, 19(suppl1):25-36.
62. Jones TS, Coffin PO: Preventing blood-borne infections through pharmacy syringe sales and safe community syringe disposal. J Amer Pharmaceut Assn 2002, 42(6 Suppl 2):S6-S9.
63. Verus G, Golovin G, Dragunova J, Ezdakov A, Mikhailov A, Skvortsov A, Flath N, T K: Access to drugs for treating hepatitis C in Russia in 2013. St. Petersburg, RF: Treatment Preparedness Coalition; 2014 [http://itpcru.org/netcat_files/File/Hepatitis%20C%20Report%202013%20ENG.pdf].